MycoLogics, Inc. is an innovative biotechnology company specializing in the development of therapeutic and prophylactic vaccines against fungal and parasitic pathogens, the discovery and isolation of novel antifungal compounds for therapeutic use and, the development of novel high throughput assays that target components of fungal cell walls. A robust pipeline of preclinical candidates to treat a variety of fungal and parasitic diseases ideally positions MycoLogics to mitigate the primary risk faced by other early stage biopharmaceutical companies who focus energies upon a single product. The diverse product portfolio at MycoLogics targets a broad spectrum of human and animal markets currently faced with unmet medical needs.

Corporate highlights include:

• Preeminent expertise in fungal biochemical, molecular and genetic science

• Mechanisms of action different from currently available drugs

• Strong U.S. intellectual property patent portfolio

• Experienced management team

MycoLogics, Inc. is headquartered in the Colorado Bioscience Park at Fitzsimmons, Aurora, CO. The premiere address between the coasts, this first biopark west of the Mississippi hosts one square mile of life sciences and is the largest medical-related redevelopment effort in the country.